a public good project by the
Synthesis
Company
of California

© 2026

Ruud Delwel | doi.page

0 works0 citations0 h-index

Ruud Delwel

Erasmus MC Cancer Institute(NL)

Publications by Year

Research Areas

Acute Myeloid Leukemia Research, Epigenetics and DNA Methylation, Protein Degradation and Inhibitors, Histone Deacetylase Inhibitors Research, Genomics and Chromatin Dynamics

Most-Cited Works

→ Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation(2010)2,713 cited
→ Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia(2011)1,506 cited
→ Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia(2004)1,376 cited
→ DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia(2010)827 cited
→ A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia(2014)705 cited
→ Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance(2005)613 cited

→ Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome(2009)

572 cited

→ Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia(2016)396 cited

→ Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity(2010)387 cited

→ The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation(2013)319 cited